<DOC>
	<DOCNO>NCT02108860</DOCNO>
	<brief_summary>Multi-center , randomize , double-blind , placebo-controlled trial evaluate efficacy abatacept achieve sustain glucocorticoid-free remission patient relapse non-severe granulomatosis polyangiitis ( Wegener 's ) ( GPA ) . Participants randomize 1:1 receive either abatacept 125 mg placebo administer subcutaneous injection week . Participants continue study treatment minimum 12 month unless experience disease relapse disease flare . Participants experience non-severe disease relapse , non-severe disease worsening , achieve remission month 6 option enter open-label trial period whereby would receive open-label abatacept .</brief_summary>
	<brief_title>Abatacept Treatment Relapsing , Non-Severe , Granulomatosis With Polyangiitis ( Wegener 's )</brief_title>
	<detailed_description>Multi-center , randomize , double-blind , placebo-controlled trial evaluate efficacy abatacept achieve sustain glucocorticoid-free remission patient relapse non-severe GPA . Patients enter trial maintain stable dose maintenance immunosuppressive agent may include methotrexate ( MTX ) , azathioprine ( AZA ) , mycophenolate ( MA ) undergo blind randomization receive abatacept placebo . Patients additionally receive prednisone 30 mg daily taper zero use standardized tapering schedule . If enrol patient experience non-severe relapse non-severe disease worsen though common closing , achieve remission month 6 , option enter open-label trial period whereby would receive abatacept conjunction maintenance immunosuppressive standardize glucocorticoid taper . Patients severe disease relapse severe disease worsen meet criterion early termination criterion remove active study treatment . Patients remain study reach criterion early termination common closing , 12 month randomization final patient . After common closing early termination , patient treat best medical judgment undergo post-treatment safety visit 3 month come study treatment .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Patients must meet least 2 5 modify ACR classification criterion GPA . These need present time study entry . The modified ACR criterion : 1 . Nasal oral inflammation , define development painful painless oral ulcer purulent bloody nasal discharge 2 . Abnormal chest radiograph , define presence nodule , fix infiltrates , cavity 3 . Active urinary sediment , define microscopic hematuria ( &gt; 5 red blood cell per high power field ) red blood cell cast 4 . Granulomatous inflammation biopsy , define histologic change show granulomatous inflammation within wall artery perivascular extravascular area ( artery arteriole ) 5 . Positive antineutrophil cytoplasmic antibody ( ANCA ) test specific proteinase3 , measure enzymelinked immunoassay 2 . Relapse GPA within 28 day prior screen active disease feature meet following definition nonsevere disease : 1 . No disease manifestation would score major element BVAS/WG 2 . Absence disease feature pose immediate threat either critical individual organ patient 's life 3 . Age 15 old 4 . Willing able comply treatment followup procedures 5 . Both woman men must willing use effective mean birth control receive treatment study . Effective contraception method include abstinence , oral contraceptive ( birth control pill ) , IUD , diaphragm , Norplant , approve hormone injection , condom , medical sterilization . 6 . Willing able provide write informed consent write assent &lt; 18 year age 1 . Presence involvement meet criterion nonsevere disease 2 . Treatment CYC within 3 month prior screen 3 . Treatment methylprednisolone 1000 mg within 28 day prior enrollment 4 . Treatment prednisone &gt; 30 mg/day &gt; 28 day immediately prior study entry 5 . Initiation dose increase maintenance immunosuppressive agent ( MTX , AZA , MA ) within 3 month prior screen 6 . Evidence active infection ( include chronic infection ) 7 . Patients pregnant nursing 8 . Known infection human immunodeficiency virus ( HIV ) , hepatitis C , positive hepatitis B surface antigen 9 . Inability comply study guideline 10 . Cytopenia : platelet count &lt; 100,000/mm3 , white blood cell count ( WBC ) &lt; 3,000/mm3 ( 3 x 109/L ) , absolute neutrophil count &lt; 1500/mm3 , hemoglobin ( Hgb ) &lt; 8.5 g/dL 11 . Chronic renal insufficiency define creatinine clearance &lt; = 20 ml/min 12 . Known current use illegal drug 13 . Other uncontrolled disease ( comorbidity ) could prevent patient fulfilling study requirement would substantially increase risk study procedures 14 . History malignancy within past five year evidence persistent malignancy , except fully excise basal cell squamous cell carcinoma skin , cervical carcinoma situ treat excised curative procedure 15 . Receipt investigational agent device within 30 day prior enrollment 5 half life investigational drug ( whichever longer ) 16 . A live vaccination few 3 month enrollment 17 . Current clinical , radiographic , laboratory evidence active tuberculosis 18 . A history active tuberculosis within past 3 year even treat 19 . A history active tuberculosis great 3 year ago unless documentation prior antituberculosis treatment appropriate duration type 20 . Latent tuberculosis unless documentation prior antituberculosis treatment appropriate duration type 21 . Latent tuberculosis currently treat isoniazid ( INH ) therapy latent tuberculosis give accord local health authority guideline ( e.g. , Center Disease Control ( CDC ) ) receive therapy 4 week less prior randomization ( Day 1 ) . Subjects positive tuberculosis screen test indicative latent tuberculosis eligible study evidence current tuberculosis chest xray screen actively treat tuberculosis INH therapy latent tuberculosis give accord local health authority guideline ( e.g. , CDC ) give least 4 week prior randomization ( Day 1 ) . These subject must complete treatment accord local health authority guideline . 22 . History herpes zoster resolve less 2 month prior enrollment 23 . Treatment rituximab biologic B cell deplete agent within past 6 month past treatment rituximab biologic B cell deplete agent B lymphocyte count remain &lt; 60 cells/uL 24 . Treatment alemtuzumab antithymocyte globulin within last 12 month 25 . Treatment intravenous immunoglobulin plasma exchange within past 3 month 26 . Treatment infliximab , etanercept , adalimumab , tocilizumab , biologic agent within past 3 month 5 half life agent ( whichever longer )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Granulomatosis polyangiitis ( Wegener 's )</keyword>
	<keyword>Granulomatosis polyangiitis</keyword>
	<keyword>GPA</keyword>
	<keyword>Wegener 's granulomatosis</keyword>
	<keyword>Wegener granulomatosis</keyword>
	<keyword>Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis</keyword>
	<keyword>ANCA Associated Vasculitis</keyword>
	<keyword>AAV</keyword>
	<keyword>Vasculitis</keyword>
	<keyword>Systemic vasculitis</keyword>
	<keyword>Systemic inflammatory disease</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Abatacept</keyword>
	<keyword>CTLA4-Ig</keyword>
	<keyword>Immunosuppressive agent</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Glucocorticoid</keyword>
	<keyword>Corticosteroid</keyword>
	<keyword>Corticosteroids</keyword>
	<keyword>Treatment</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Anti Inflammatory Agents</keyword>
</DOC>